A Phase 2 interventional study of Alpha1-Proteinase Inhibitor (Human) in Cystic Fibrosis, sponsored by Grifols Therapeutics LLC. Completed. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2014-08-21.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this trial is to determine the optimal region of the lung for depositing Prolastin (alpha-1 antitrypsin; AAT) by inhalation in order to treat cystic fibrosis (CF). The AKITA® nebulizer has settings which can be varied to target the inhaled drug to either the deep lung or to the upper airways in a one to one randomization. The study will measure how much of the activity of the enzyme elastase is inhibited by AAT.
The optimum deposition site (bronchial or peripheral) in CF patients for AAT will be investigated by measuring several parameters in induced sputum. The study will start with a 2 week run-in period in which the planned 60 patients inhale isotonic saline once daily. This period is followed by a 4 week treatment period where 30 patients inhale AAT for peripheral deposition and 30 patients inhale AAT for bronchial deposition. Six patients in each group will be asked to collect spontaneous sputum at home.
Twenty-five milligrams of AAT will be deposited at one of the two target sites using the AKITA® device. The inhalation should take place in the evening between 18.00 and 23.00 h.
Patients will inhale saline once daily for 2 weeks (run-in period) followed by 4 weeks of once daily inhalation of AAT. Induced sputum will be collected at visits to the clinic at the start of the run-in, at the start of AAT treatment, and at 2 and 4 weeks after the start of AAT treatment.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
This study's enrollment of 72 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
First submitted before Grifols Therapeutics LLC became part of Grifols.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
Drug: Alpha1-Proteinase Inhibitor (Human)
Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
Drug: Alpha1-Proteinase Inhibitor (Human)
25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
Also known as: Prolastin®, Alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007, A1AT, NDC 13533-601-30, NDC 13533-601-35
Change in Free Elastase in Induced Sputum From Baseline to Week 4
Time frame: Baseline vs Week 4
Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4
Time frame: Baseline vs Week 4
Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4
Time frame: Baseline vs Week 4
Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4
Time frame: Week 4
Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4
Time frame: Baseline vs Week 4
Change in Neutrophil Number in Induced Sputum From Baseline at Week 4
Time frame: Baseline vs Week 4
This study was performed in 8 study centers in Germany.
| Milestone | Peripheral Deposition | Bronchial Deposition |
|---|---|---|
| Started | 37 | 35 |
| Completed | 28 | 28 |
| Not completed | 9 | 7 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: No sputum, devise issues, exacerbation | 3 | 4 |
| ug/mL | Peripheral Deposition | Bronchial Deposition |
|---|---|---|
| Change in Free Elastase in Induced Sputum From Baseline to Week 4 | -7.42 ± 29.96 | 6.11 ± 31.30 |
| ug/mL | Group 1 | Group 2 |
|---|---|---|
| Change in Alpha-1-anti-trypsin (A1AT) Activity in Induced Sputum From Baseline at Week 4 | 16741 ± 33583 | 6469 ± 18999 |
| ug/mL | Group 1 | Group 2 |
|---|---|---|
| Change in Total Immunoglobulin G (IgG) Fragments in Induced Sputum From Baseline at Week 4 | 0.005 ± 1.10 | -0.48 ± 1.53 |
| CFU/g | Group 1 | Group 2 |
|---|---|---|
| Change in Total Bacterial Load in Induced Sputum From Baseline to Week 4 | 22673275.8 ± 253455845.23 | 5021353.2 ± 130686274.77 |
| CFU/g | Group 1 | Group 2 |
|---|---|---|
| Change in Pseudomonas Load in Induced Sputum From Baseline at Week 4 | -40.1 ± 808.2 | -22.3 ± 772.4 |
| percentage of change | Group 1 | Group 2 |
|---|---|---|
| Change in Neutrophil Number in Induced Sputum From Baseline at Week 4 | -20.8 ± 30.3 | -8.2 ± 20.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peripheral Deposition | — | 0/37 (0%) | 10/37 (27%) |
| Bronchial Deposition | — | 0/35 (0%) | 13/35 (37.1%) |
| Event | Peripheral Deposition | Bronchial Deposition |
|---|---|---|
| NasopharyngitisInfections and infestations | 1/37 | 5/35 |
| FatigueGeneral disorders | 0/37 | 2/35 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/37 | 2/35 |
| Back painMusculoskeletal and connective tissue disorders | 2/37 | 0/35 |
| Conjunctivitis AllergicEye disorders | 0/37 | 1/35 |
| Abdominal PainGastrointestinal disorders | 0/37 | 1/35 |
| DiarrhoeaGastrointestinal disorders | 0/37 | 1/35 |
| GingivitisGastrointestinal disorders | 0/37 | 1/35 |
| SinusitisInfections and infestations | 0/37 | 1/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/37 | 1/35 |
| Age, Categorical(Participants) | Peripheral Deposition | Bronchial Deposition | Total |
|---|---|---|---|
| <=18 years | 10 | 10 | 20 |
| Between 18 and 65 years | 27 | 25 | 52 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Peripheral Deposition | Bronchial Deposition | Total |
|---|---|---|---|
| Mean | 23.78 ± 7.54 | 27.42 ± 9.78 | 25.46 ± 8.84 |
| Sex: Female, Male(Participants) | Peripheral Deposition | Bronchial Deposition | Total |
|---|---|---|---|
| Female | 21 | 19 | 40 |
| Male | 16 | 16 | 32 |
| Region of Enrollment(participants) | Peripheral Deposition | Bronchial Deposition | Total |
|---|---|---|---|
| Germany | 37 | 35 | 72 |
| Free Elastase during the Run-In Phase(µg/mL) | Peripheral Deposition | Bronchial Deposition | Total |
|---|---|---|---|
| Week 0 | 36.6 ± 35.9 | 35.9 ± 38.8 | 36.2 ± 36.9 |
| Week 2 | 32.7 ± 31.7 | 25.0 ± 20.1 | 29.1 ± 27.0 |
| Absolute Change | -4.0 ± 21.3 | -10.9 ± 36.9 | -7.25 ± 29.6 |
No study locations are listed for this record.
The record gives a start of Dec 2003, a primary completion of Jun 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 10 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin